


S.M.A.R.T.[®]
VASCULAR STENT SYSTEMS

For the Treatment of Superficial Femoral Artery (SFA) or Iliac Lesions

When Trust Is Put in You, Put Yours in What's Been Proven.

Featuring Results of the STROLL* Study



THE STENT WITH THE STATS

Cordis[®]

* The S.M.A.R.T.[®] Nitinol Self-expanding Stent in the Treatment of Obstructive Superficial Femoral Artery Disease (STROLL) study.

Contents

STENT	3
Design	4
Stability	5
Radial Force	6
Fracture Rate	7
COMPETITORS	8
OUTCOMES	9
STROLL Study	10
Clinical	11
Patient	12
ORDERING INFORMATION	13
S.M.A.R.T. CONTROL® and S.M.A.R.T.® Vascular Stent Systems	14

STENT

Design

Stability

Radial Force

Engineering

Engineered to Perform

36 Struts

Each circumferential ring contains 36 struts, providing radial force and scaffolding.

6 Alternating Bridges


Each ring is connected by 6 bridges for greater longitudinal stability.¹

Offset Peak-to-Valley Design

The offset design provides smooth lumen and stent contourability without strut overlapping or fish-scaling.

Segmented Micromesh Geometry

The unique micromesh design allows for consistent radial force, uniform scaffolding, and small cell size.



Optimizing Outcomes through Unique Stent Design

Scaffolding

Smaller cell size and uniform coverage can help prevent vessel prolapse.¹

Longitudinal stability

Greater stability minimizes stretching at deployment, thereby increasing placement accuracy.¹

Radial force


The stent's ability to resist compression maintains luminal gain.¹

¹ Cordis 2013 Data on file

Delivering Superior Stability by Design

Up to 300% greater stability for accurate placement with the S.M.A.R.T.® Vascular Stent Systems.

Longitudinal stability¹



A foundation built on uniform scaffolding and small cell size.

Cordis S.M.A.R.T.® Vascular Stent

36 Struts/6 Bridges




Medtronic Protégé™ EverFlex™ Stent

32 Struts/4 Bridges



Terumo MISAGO® Stent

8 Struts/2 Bridges




Bard LifeStent® Stent

36 Struts/4 Bridges



Cook Zilver 635® Stent

24 Struts/4 Bridges




¹ Cordis 2013 Data on file


Built With Unmatched Radial Force

Up to 118% greater radial force than other nitinol stents with the S.M.A.R.T.® Vascular Stent Systems.

Radial force¹



Designed to Maintain Luminal Gain




S.M.A.R.T.® Vascular Stent Systems are designed to **maintain luminal gain.**

1. Cordis 2013 Data on file


Lower Fracture Rate. Higher Satisfaction.

S.M.A.R.T.® Vascular Stent Systems have a low fracture rate maintained out to 3 years in the STROLL Study.

Stent fracture rate



The Stent Fracture Grading Scale



Stent strut fractures are commonly categorized into five types.

Adapted from Rocha-Singh et al²


- Type I**
One strut fracture
- Type II**
Multiple strut fractures
- Type III**
Complete transverse linear fracture
- Type IV**
Complete transverse linear fracture with displacement
- Type V**
Complete transaxial fracture

1. Cordis 2013 Data on file
2. Rocha-Singh KJ et al; on behalf of VIVA Physicians, Inc. Catheter Cardiovasc Interv. 2007;69:910-919


Fracture Rates With Other Stents

In clinical trials, severe fractures were observed in two of our competitors.

EverFlex® Stent (DURABILITY I Trial) at 1 year¹



LifeStent® Stent (RESILIENT Trial—all phases and arms) at 18 months²



1. Bosiers M et al. J Endovasc Ther. 2009;16:261-269.
 2. The RESILIENT Randomized Trial: Three-Year Results, Resilient LINC Presentation 2013.
 The third-party trademarks used herein are trademarks of their respective owners.

OUTCOMES

STROLL Study
Clinical Outcomes
Patient Outcomes

When Trust Is Put in You, Put Yours in What's Been Proven.

Conducted over 3 years, the STROLL* Study proved that S.M.A.R.T.® Vascular Stent Systems provided effective SFA revascularization.¹

Clinical & Patient Outcomes

Clinical Outcomes	1 year	2 years	3 years
Primary patency [†]	81.7%	74.9%	72.7%
Freedom from TLR	87.6%	80.3%	78.5%
Stent fracture rate	2% (all Type I)	2% (all Type I)	3.6% (all Type I)
Patient Outcomes	1 year	2 years	3 years
Patients with minimal or no PAD symptoms [‡]	76.6%	81.8%	77.8%
Patients with normal ABI (>0.8)	81.0%	80.7%	76.5%

“The STROLL outcomes both meet and exceed our expectations for patients with symptomatic disease of the superficial femoral artery.”

— Dr William A. Gray,[†] President of the Lankenau Heart Institute, Pennsylvania

Quality-of-Life (QoL) Outcomes

As reported by patients, the overall health-related QoL benefit was very large and sustained out to 3 years.

- 10-15 years of age on generic measures
- ~4x the Minimum Clinically Importance Difference (MCID) on PAD specific scales


* The S.M.A.R.T.® Nitinol Self-expanding Stent in the Treatment of Obstructive Superficial Femoral Artery Disease (STROLL) study.
 † A principal investigator of the STROLL study.
 ‡ Defined as no significant reduction in flow detectable by duplex ultrasound and no further clinically driven target lesion revascularization.
 § Defined as Rutherford-Becker classification 0 or 1.

1. Cordis 2013 Data on file

The Stent With the Difference Makers


High primary patency rate maintained out to 3 years in the STROLL Study with the S.M.A.R.T.® Vascular Stent Systems¹.

Primary patency



Strong rate of freedom from TLR maintained out to 3 years in the STROLL study¹.


Freedom from TLR



1. Cordis 2013 Data on file

Providing Critical Patient Outcomes


Minimal or no signs of PAD* in 3 of 4 patients maintained out to 3 years in the STROLL Study as measured using Rutherford-Becker classification¹.



ORDERING INFORMATION

S.M.A.R.T. CONTROL[®] and S.M.A.R.T.[®] Vascular Stent Systems

Improvement in ABI was sustained out to 3 years.



Normal ABI in over 3 out of 4 patients out to 3 years when treated with the S.M.A.R.T.[®] Vascular Stent.

81.0%, 80.7% and 76.5% of patients had ABI >0.8 at one, two and three years, respectively, after deployment of S.M.A.R.T.[®] Vascular Stent Systems.

*Defined as Rutherford-Becker classification 0 or 1.

¹ Cordis 2013 Data on file

S.M.A.R.T. CONTROL® and S.M.A.R.T.® Vascular Stent Systems

Product Description			
Type	MicroMesh Geometry, Segmented Design	Sheath Compatibility	6F (6-10mm)
Material	Nitinol, with MicroMarker Technology	Guide Catheter Compatibility	8F (6-10mm)
Maximum Guidewire	0.035"	Stent Diameters	6-10mm (Stent diameter should be 1-2mm greater than vessel diameter)
Stent Lengths	20 - 150mm	Stent Delivery System Working Lengths	80cm (S suffix) & 120cm (M suffix)
Stent Delivery Systems	Delivery Handle: 20-100mm Stent lengths. Pin and Pull: 120 and 150mm Stent Lengths		

20mm Stent Length

Expanded Stent Diameter (mm)	Recommended Vessel Size (mm)	Indication		SDS Length (cm)	Catalog Number
		Iliac	SFA		
6	4-5	•	•	80	C06020SL
				120	C06020ML
7	5-6	•	•	80	C07020SL
				120	C07020ML
8	6-7	•	•	80	C08020SL
				120	C08020ML
9	7-8	•		80	C09020SL
				120	C09020ML
10	8-9	•		80	C10020SL
				120	C10020ML

30mm Stent Length

Expanded Stent Diameter (mm)	Recommended Vessel Size (mm)	Indication		SDS Length (cm)	Catalog Number
		Iliac	SFA		
6	4-5	•	•	120	C06030ML
				80	C06030SL
7	5-6	•	•	120	C07030ML
				80	C07030SL
8	6-7	•	•	120	C08030ML
9	7-8	•		120	C09030ML
				80	C09030SL
10	8-9	•		120	C10030ML
				80	C10030SL

40mm Stent Length

Expanded Stent Diameter (mm)	Recommended Vessel Size (mm)	Indication		SDS Length (cm)	Catalog Number
		Iliac	SFA		
6	4-5	•	•	120	C06040ML
				80	C06040SL
7	5-6	•	•	120	C07040ML
				80	C07040SL
8	6-7	•	•	120	C08040ML
				80	C08040SL
9	7-8	•		120	C09040ML
				80	C09040SL
10	8-9	•		120	C10040ML
				80	C10040SL

60mm Stent Length

Expanded Stent Diameter (mm)	Recommended Vessel Size (mm)	Indication		SDS Length (cm)	Catalog Number
		Iliac	SFA		
6	4-5	•	•	120	C06060ML
				80	C06060SL
7	5-6	•	•	120	C07060ML
				80	C07060SL
8	6-7	•	•	120	C08060ML
				80	C08060SL
9	7-8	•		120	C09060ML
				80	C09060SL
10	8-9	•		120	C10060ML
				80	C10060SL

80mm Stent Length

Expanded Stent Diameter (mm)	Recommended Vessel Size (mm)	Indication		SDS Length (cm)	Catalog Number
		Iliac	SFA		
6	4-5	•	•	120	C06080ML
				80	C06080SL
7	5-6	•	•	120	C07080ML
				120	C07080ML
8	6-7	•	•	120	C08080ML
				80	C08080SL

100mm Stent Length

Expanded Stent Diameter (mm)	Recommended Vessel Size (mm)	Indication		SDS Length (cm)	Catalog Number
		Iliac	SFA		
6	4-5	•	•	120	C06100ML
				80	C06100SL
7	5-6	•	•	120	C07100ML
				80	C07100SL
8	6-7	•	•	120	C08100ML
				80	C08100SL

120mm Stent Length

Expanded Stent Diameter (mm)	Recommended Vessel Size (mm)	Indication		SDS Length (cm)	Catalog Number
		Iliac	SFA		
6	4-5		•	120	C06120ML
7	5-6		•	120	C07120ML
8	6-7		•	120	C08120ML

150mm Stent Length

Expanded Stent Diameter (mm)	Recommended Vessel Size (mm)	Indication		SDS Length (cm)	Catalog Number
		Iliac	SFA		
6	4-5		•	120	C06150ML
7	5-6		•	120	C07150ML
8	6-7		•	120	C08150ML

CAUTION: Federal (USA) law restricts this device to sale by or on the order of a physician.

Important Information: Prior to use, refer to the instructions for use supplied with this device for indications, contraindications, side effects, suggested procedure, warnings and precautions.

CORDIS, the Cordis LOGO, S.M.A.R.T. and S.M.A.R.T. CONTROL are trademarks of Cordis and may be registered in the US and/or in other countries. All other trademarks are the property of their respective owners. © 2023 Cordis. All Rights Reserved. 100605281 2/2023

Cordis®